Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
NCT04833959 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2024-06-21
Summary
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
Conditions
- Pancreas Cancer
Interventions
- DRUG
-
89Zr-panitumumab
Imaging Agent
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Andrei Iagaru · Stanford Universiy
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-26
- Primary Completion
- 2024-03-31
- Completion
- 2024-03-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
NCT01783171 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
NCT04888312 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
ZN-c3 + Gemcitabine in Pancreatic Cancer
NCT06015659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
NCT02907099 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
NCT00547144 ·Status: COMPLETED ·Phase: PHASE1
-
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
NCT07175389 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
NCT01146054 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
NCT03989310 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NCT02562898 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
NCT03086369 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer
NCT04381130 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
NCT04233866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT02194829 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vorinostat Plus Radiation Therapy in Pancreatic Cancer
NCT00831493 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
NCT00005926 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas
NCT01985958 ·Status: COMPLETED ·Phase: NA
-
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
NCT02336087 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
NCT04665947 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma
NCT03915444 ·Status: COMPLETED ·Phase: PHASE2
-
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00005832 ·Status: COMPLETED ·Phase: PHASE2
-
Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment
NCT00288925 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
NCT00005591 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .
NCT01130701 ·Status: WITHDRAWN ·Phase: PHASE2
-
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
NCT00841035 ·Status: TERMINATED ·Phase: PHASE2
-
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00003546 ·Status: COMPLETED ·Phase: PHASE2